Innovative Drug Development Initiative (IDDI) Workstreams 

The IDDI is a global, collaborative forum where representatives from academia, the pharmaceutical industry (established and emerging biotechnology), and drug regulators openly discuss questions surrounding the future of trials involving novel drugs. See our IDDI Special collection on Clinical Trial Design: Past, Present, and Future.

We believe in the power of early and ongoing dialogue with all stakeholders in the drug development process, including the crucial perspective of patients and their advocates. The IDDI aspires to explore novel approaches for combating and treating PVD and PH, focusing strongly on patient needs. There are eight IDDI Workstreams, each assigned to address various challenges PH patients face.  

Task Forces 

Our Disease and Specialty Task Forces focus on research into specific areas of PVD. They support us in understanding and implementing our vision and mission. Our Regional Task Forces focus on the key challenges facing patients, clinicians and researchers in their country or region. Several Regional Task Forces were impacted by the Covid pandemic and are currently inactive, but some are in the process of re-forming, such as the South East Asia Task Force and China Task Force. 

Find out more about each IDDI Workstream or Task Force below. PVRI members who are interested in contributing are encouraged to join. 

Reset filters

Paediatric Clinical Trial Design & Endpoints Workstream

Leaders

Pegah Nowbakht , Ironwood Pharmaceuticals
Steve Abman , Children’s Hospital Colorado

Supported by

Maria Jesus Del Cerro , Hospital Universitario Ramon y Cajal
Shahin Moledina, GOSH
Christina Garnett , FDA
Sylvia Nikkho , Bayer
Sidra Hoffman , Gossamer Bio
Innovative Drug Development Initiative (IDDI) Workstreams

Paediatric Task Force

Leaders

Shahin Moledena, Great Ormond Street Hospital
Maria del Cerro, Ramon y Cajal University Hospital
Disease and Specialty Task Forces

Real World Evidence/Data Workstream

Leaders

Kellie Morland, United Therapeutics Corporation, USA
Greg Elliott, University of Utah / Intermountain Health, USA

Work Group 1

Athénaïs Boucly (Leader), Université Paris-Saclay / Assistance Publique Hôpitaux de Paris, France
Scott Visovatti (Leader), The Ohio State University, USA
Charles Fauvel, Centre Hospitalier Universitaire Charles Nicolle / Université de Rouen, France
Victor Moles, University of Michigan, USA
Rebecca Vanderpool, The Ohio State University, USA

Work Group 2

Jason Weatherald (Leader), University of Alberta, Canada
Jean Elwing (Leader), University of Cincinnati, USA
Evan Patrick Minty, University of Calgary, Canada
Arun Jose, University of Cincinnati, USA
Jose Leonidas Alves Jr, University of São Paulo Medical School, Brazil
Junyan Qian, Chinese Academy of Medical Sciences & Peking Union Medical College, China
Mengtao Li, Chinese Academy of Medical Sciences & Peking Union Medical College, China
Valentina Mercurio, Federico II University, Italy
Jason Zelt, University of Ottawa, Canada

Work Group 3

Sandeep Sahay (Leader), Houston Methodist Hospital, USA
Stephen Mathai (Leader), Johns Hopkins University School of Medicine, USA
Paul Williams, Milpark Hospital, South Africa
Sivadasanpillai Harikrishnan, Sree Chitra Tirunal Institute for Medical Sciences and Technology, India
Zhi-Cheng Jing, Chinese Academy of Medical Sciences and Peking Union Medical College, China
Geoff Strange, The University of Notre Dame, Australia
Tomas Pulido, Ignacio Chávez National Heart Institute, Mexico

Work Group 4

Kari Gillmeyer (Leader), Boston University Chobian & Avedisian School of Medicine / Center for Healthcare Organization & Implementation Research, USA
Christian Gerges (Leader), Medical University of Vienna, Austria
Lukas Hobohm, Johannes Gutenberg University of Mainz, Germany
Roberto Badagliacca, Sapienza University of Rome, Italy
Edmund Lau, University of Sydney, Australia
Meghan Cirulis, Intermountain Medical Center / University of Utah, USA
Innovative Drug Development Initiative (IDDI) Workstreams
17